全文获取类型
收费全文 | 306774篇 |
免费 | 18101篇 |
国内免费 | 449篇 |
专业分类
耳鼻咽喉 | 4310篇 |
儿科学 | 10616篇 |
妇产科学 | 10392篇 |
基础医学 | 46312篇 |
口腔科学 | 7852篇 |
临床医学 | 24863篇 |
内科学 | 58112篇 |
皮肤病学 | 6447篇 |
神经病学 | 21797篇 |
特种医学 | 12157篇 |
外国民族医学 | 43篇 |
外科学 | 49226篇 |
综合类 | 7793篇 |
现状与发展 | 1篇 |
一般理论 | 161篇 |
预防医学 | 20171篇 |
眼科学 | 7227篇 |
药学 | 21567篇 |
中国医学 | 757篇 |
肿瘤学 | 15520篇 |
出版年
2019年 | 2398篇 |
2018年 | 3805篇 |
2017年 | 2813篇 |
2016年 | 3231篇 |
2015年 | 3662篇 |
2014年 | 4817篇 |
2013年 | 7538篇 |
2012年 | 9606篇 |
2011年 | 9995篇 |
2010年 | 6441篇 |
2009年 | 5791篇 |
2008年 | 9093篇 |
2007年 | 10041篇 |
2006年 | 9874篇 |
2005年 | 9480篇 |
2004年 | 9162篇 |
2003年 | 8703篇 |
2002年 | 8263篇 |
2001年 | 13781篇 |
2000年 | 14133篇 |
1999年 | 11777篇 |
1998年 | 3100篇 |
1997年 | 2745篇 |
1996年 | 2616篇 |
1995年 | 2637篇 |
1994年 | 2446篇 |
1992年 | 8631篇 |
1991年 | 8773篇 |
1990年 | 8552篇 |
1989年 | 8355篇 |
1988年 | 7572篇 |
1987年 | 7350篇 |
1986年 | 6961篇 |
1985年 | 6753篇 |
1984年 | 4895篇 |
1983年 | 4265篇 |
1982年 | 2534篇 |
1979年 | 4548篇 |
1978年 | 3296篇 |
1977年 | 2809篇 |
1976年 | 2543篇 |
1975年 | 2918篇 |
1974年 | 3440篇 |
1973年 | 3466篇 |
1972年 | 3204篇 |
1971年 | 3027篇 |
1970年 | 2900篇 |
1969年 | 2639篇 |
1968年 | 2598篇 |
1967年 | 2414篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
4.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
5.
Amarpali Brar Angelika Gruessner Deborah Adey Fasika Tedla Ernie Yap Dheeraj Kaul Nabil Sumrani Devon John Moro O. Salifu 《Transplantation proceedings》2021,53(3):913-919
There is an increase in older-adult renal transplant recipients in United States. The objective of this study was to assess the association between physical function (PF) and patient survival in renal transplant recipients who are aged 65 years or older. Using United Network for Organ Sharing (UNOS) data from 2007 to 2016, renal transplant recipients aged 65 years or older were included. Multivariable Cox regression was used to assess associations between survival and functional status adjusted for age, sex, race, donor quality, diabetes, and dialysis vintage. The study identified 26,721 patients. Patient survival was significantly higher in recipients who needed no assistance and lowest in patients in need of total assistance (P < .0001). In deceased donor (DD) transplants, the relative risk for mortality was 2.06 (1.74-2.43) for total assistance and 1.17 (1.08-1.28) for moderate assistance compared to no assistance (P < .0001). In living donor (LD) transplants, the relative risk of mortality was 1.38 (0.78-2.42) for patients needing total assistance and 1.37 (1.14-1.65) for patients needing moderate assistance compared to patients who did not need assistance (0.003). PF is an independent predictor of post-transplant mortality. Assessment of older potential renal transplant recipients should include assessment and standardization of functional status to counsel about post-transplant survival. 相似文献
6.
7.
8.
9.
10.
Paula C. Salamone Agustina Legaz Lucas Sedeo Sebastin Moguilner Matías Fraile-Vazquez Cecilia Gonzalez Campo Sol Fittipaldi Adrin Yoris Magdalena Miranda Agustina Birba Agostina Galiani Sofía Abrevaya Alejandra Neely Miguel Martorell Caro Florencia Alifano Roque Villagra Florencia Anunziata Maira Okada de Oliveira Ricardo M. Pautassi Andrea Slachevsky Cecilia Serrano Adolfo M. García Agustín Ibaez 《The Journal of neuroscience》2021,41(19):4276
Recent frameworks in cognitive neuroscience and behavioral neurology underscore interoceptive priors as core modulators of negative emotions. However, the field lacks experimental designs manipulating the priming of emotions via interoception and exploring their multimodal signatures in neurodegenerative models. Here, we designed a novel task that involves interoceptive and control-exteroceptive priming conditions followed by post-interoception and post-exteroception facial emotion recognition (FER). We recruited 114 participants, including healthy controls (HCs) as well as patients with behavioral variant frontotemporal dementia (bvFTD), Parkinson''s disease (PD), and Alzheimer''s disease (AD). We measured online EEG modulations of the heart-evoked potential (HEP), and associations with both brain structural and resting-state functional connectivity patterns. Behaviorally, post-interoception negative FER was enhanced in HCs but selectively disrupted in bvFTD and PD, with AD presenting generalized disruptions across emotion types. Only bvFTD presented impaired interoceptive accuracy. Increased HEP modulations during post-interoception negative FER was observed in HCs and AD, but not in bvFTD or PD patients. Across all groups, post-interoception negative FER correlated with the volume of the insula and the ACC. Also, negative FER was associated with functional connectivity along the (a) salience network in the post-interoception condition, and along the (b) executive network in the post-exteroception condition. These patterns were selectively disrupted in bvFTD (a) and PD (b), respectively. Our approach underscores the multidimensional impact of interoception on emotion, while revealing a specific pathophysiological marker of bvFTD. These findings inform a promising theoretical and clinical agenda in the fields of nteroception, emotion, allostasis, and neurodegeneration.SIGNIFICANCE STATEMENT We examined whether and how emotions are primed by interoceptive states combining multimodal measures in healthy controls and neurodegenerative models. In controls, negative emotion recognition and ongoing HEP modulations were increased after interoception. These patterns were selectively disrupted in patients with atrophy across key interoceptive-emotional regions (e.g., the insula and the cingulate in frontotemporal dementia, frontostriatal networks in Parkinson''s disease), whereas persons with Alzheimer''s disease presented generalized emotional processing abnormalities with preserved interoceptive mechanisms. The integration of both domains was associated with the volume and connectivity (salience network) of canonical interoceptive-emotional hubs, critically involving the insula and the anterior cingulate. Our study reveals multimodal markers of interoceptive-emotional priming, laying the groundwork for new agendas in cognitive neuroscience and behavioral neurology. 相似文献